Newsletter insight
UK Biotechnology and Technology Transactions Attract Acquisition Interest
Perspectives from the HPC business newsletter.
← All business news
On 19 October, Germany's Merck agreed to acquire UK-based Silence Therapeutics in an approximately $1.3 billion all-cash transaction, strengthening its presence in RNA-targeting medicines. Separately, Intuit's acquisition of UK financial technology startup...
On 19 October, Germany's Merck agreed to acquire UK-based Silence Therapeutics in an approximately $1.3 billion all-cash transaction, strengthening its presence in RNA-targeting medicines. Separately, Intuit's acquisition of UK financial technology startup Sequence highlighted continued interest in British software businesses with specialised AI-enabled commercial applications.
Companies pursuing acquisitions, fundraising or strategic partnerships require valuation models, financial due diligence and transaction-risk assessments. HPC supports corporate finance teams with financial modelling, asset valuation and transaction analysis for complex deals at a project cost of $920,000.